3 - Telix Pharmaceuticals Ltd (0002007191) (Issuer)

3 - Telix Pharmaceuticals Ltd (0002007191) (Issuer)

3 - Telix Pharmaceuticals Ltd (0002007191) (Issuer)

4 - Telix Pharmaceuticals Ltd (0002007191) (Issuer)

4 - Telix Pharmaceuticals Ltd (0002007191) (Issuer)

3 - Telix Pharmaceuticals Ltd (0002007191) (Issuer)

3 - Telix Pharmaceuticals Ltd (0002007191) (Issuer)

3 - Telix Pharmaceuticals Ltd (0002007191) (Issuer)

3 - Telix Pharmaceuticals Ltd (0002007191) (Issuer)

3 - Telix Pharmaceuticals Ltd (0002007191) (Issuer)

MELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 20261. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as a NED. Mr. Gill is a life sciences executive with over 35 years' experience in senior general management and financial leadership roles across commercial and clinical-stage biopharmaceutical (including radiopharmaceuticals) and medical device companies. He current

MELBOURNE, Australia and INDIANAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today. Dr. Schaffer has been CTO at ARTMS Inc. (ARTMS) (acquired by Telix in 2024) for the past seven years, as well as Director, Life Science at TRIUMF, Canada's particle accelerator research centre, since 2012. Based in Vancouver, Canada, Dr. Schaffer is widely recognized for his role in the buildout and transformation of the TRIUMF Life Sciences program, which included design and construction of a major multi-cyclotr

MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years' global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC

MELBOURNE, Australia and INDIANAPOLIS, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces it has completed the acquisition from antibody engineering company ImaginAb, Inc. (ImaginAb). The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enhance existing innovation capabilities1. This transaction delivers a pipeline of drug candidates against validated cancer targets including DLL32 and integrin αvβ63, as well as a panel of other agents against novel targets in early discovery stage.

4 - Telix Pharmaceuticals Ltd (0002007191) (Issuer)

MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026). Q2 2026 Highlights1 Group revenue of US$247 million, up 7% quarter-over-quarter (QoQ) and up 21% year-over-year (YoY). Precision Medicine continues to deliver strong growth, revenue of US$202 million, up 9% QoQ and up 30% YoY. Telix expects FY 2026 revenue and other income to be in excess of US$1 billion, with revenue tracking in line with the upper end of FY 2026 guidance of US$950 million to US$970 million plus US$40 million non-refund

First patient dosed in Phase 3 LUTEON1 trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC).LUTEON is the first Phase 3 study of a CAIX2-targeted radiopharmaceutical therapy in ccRCC. MELBOURNE (Australia) and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announced that the first patient has been dosed with TLX250-Tx (lutetium-177 (177Lu) girentuximab tetraxetan) in the LUTEON study, the first radiopharmaceutical therapy to enter Phase 3 development for ccRCC. LUTEON is a randomized, prospective, open label, multi-center study evaluating a CAIX-targeting radionuclide therapy in pat

FDA and Telix align on advancement into Part 2 of the ProstACT Global Phase 3 study in the United States.FDA agrees with the clinical protocol and proposed statistical framework across three standard-of-care combination cohorts.Part 2 (randomized cohort) continues to recruit in jurisdictions where the study has regulatory approval. MELBOURNE, Australia and INDIANAPOLIS, July 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals (ASX: TLX, NASDAQ:TLX, "Telix") today announced the successful outcome of a Type B meeting with the United States (U.S.) Food and Drug Administration (FDA) to review the Part 1 safety and dosimetry data and Part 2 protocol design of the ProstACT Global Phase 3 trial o

MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address these. David N. Cade, MD, Telix Group Chief Medical Officer will provide a clinical update, which will be followed by a fireside chat with Nelleke Tolboom, MD, Nuclear Medicine physician and academic faculty member at UMC Utrecht (Netherlands) and Josef Pichler, MD, Head of the Neuro-oncological Center at Kepler University Hospital Linz (Austria). The presentation will be followed by Q&A with

Partnership to evaluate Telix's innovative precision medicine products and candidates in combination with United Imaging's advanced scanner platforms.Initial focus on TLX101-Px (Pixclara®1, Floretyrosine F 18) in the U.S.Framework to support potential co-development, validation, and deployment of integrated theranostics workflows. MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") and United Imaging Healthcare North America, Inc. ("United Imaging") today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused

Telix's first-in-class lutetium radio antibody-drug conjugate (rADC) candidate, TLX591-Tx, demonstrates acceptable tolerability across all standard-of-care (SoC) combination cohorts, with no new safety signals.Findings support feasibility of TLX591-Tx in combination with contemporary SoC in post-ARPI metastatic castration-resistant prostate cancer (mCRPC).Part 2 (randomized treatment expansion) is actively dosing patients in jurisdictions where health authority approval has been granted1. MELBOURNE, Australia and INDIANAPOLIS, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, ", Telix", ) announces the oral presentation of Part 1 safety, dosimetry and

MELBOURNE, Australia and INDIANAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will participate in the upcoming William Blair 46th Annual Growth Stock Conference in Chicago, IL and in the Jefferies Global Healthcare Conference in New York, NY. Presentation details: William Blair 46th Annual Growth Stock ConferenceDate: June 2, 2026Time: 8:00 a.m. CDT (9:00 a.m. EDT, 11:00 p.m. AEST) Jefferies Global Healthcare ConferenceDate: June 3, 2026Time: 11:40 a.m. EDT (1:40 a.m. AEST, June 4) Each session will be webcast live, and accessible through Telix's Inve

IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment.Maximum dose reached with no dose-limiting toxicities observed.TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT, which is actively dosing patients with recurrent glioblastoma. MELBOURNE, Australia and INDIANAPOLIS, May 19, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that the IPAX-2 study1 of TLX101-Tx (¹³¹I-iodofalan) in patients with newly diagnosed glioblastoma has completed patient enrolment. No dose-limiting toxicities (DLTs) have been observed to date, including with two doses of 5GBq (total administered activity of 10GBq), the maximum adm

Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes. MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ:EDAP, "EDAP")) and Profound Medical Corp. (NASDAQ:PROF, TSX:PRN, "Profound")

, May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (NASDAQ:EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited ("Telix") to explore joint clinical research activities and physician education focused on the combination of EDAP's Focal One Robotic HIFU and Telix's PSMA PET imaging products in the management of prostate cancer. The initial area of investigational focus is expected to study the combination of PSMA PET diagnostic imaging scans within the Focal One HIFU treatment workflow to optimize treatment planning, deliver a precise, image-guided focal therapy treatment, and monitor responses after treatment and

Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed. Key findings includ

MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, ", Telix", ) today announces its financial results for the year ended December 31, 2025. FY 2025 key results1 Group performance2: Double-digit revenue growth and positive adjusted operating cash flow Revenue of US$803.8 million, up by 56%3 and achieving upsized full year guidance4.US$157.1 million invested in research and development (R&D) product development for late-stage therapeutics and precision medicine pipeline assets5, in line with stated FY 2025 guidance.Adjusted EBITDA6 of US$39.5 million, reflective of increased operating expenditure driven by strategi

MELBOURNE, Australia and INDIANAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") advises that it will release its full year results for the period ended 31 December 2025 on Friday, 20 February 2026 AEDT (Thursday, 19 February 2026 EST). An investor webcast and conference call will be held at 9:30 a.m. AEDT, Friday, 20 February 2026 (5:30 p.m. EST, Thursday, 19 February 2026).  Participants can register at the following link: https://edge.media-server.com/mmc/p/famdpwzh About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceu

NEW YORK, Nov. 30, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds purchasers or acquirers of Telix Pharmaceuticals Ltd. (NASDAQ:TLX) ("Telix") American Depositary Shares ("ADS") between February 21, 2025 and August 28, 2025 (the "Class Period") have until January 9, 2026 to seek appointment as lead plaintiff. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Allegations: The lawsuit alleges violations of the Securities Exchange Act of 1934, claiming that Telix and its executives: Overstated progress on the company's prostate cancer therapeutic candidates.Overstated the quality of its supply chain and partner operations. Key Events: On Febr

MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, ", Telix", ) today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise. H1 2025 key results1 Group performance2: Reflects strategic investment for long-term value creation Revenue of $390.4 million, up by 63%3 and on track to meet full year guidance4.Group gross profit margin of 53% reflects product mix change to include third-party RLS sales. Illuccix® margin remains stable.Adjusted EBITDA5 of $21.1 million, reflective of increased operating expenditure driven by strategic acquisitions, inves

MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025. An investor webcast and conference call will be held at 9.30am AEST on Thursday 21 August 2025 (7.30pm EDT Wednesday 20 August 2025).    Participants can register for the webcast at the following link: https://edge.media-server.com/mmc/p/x4gytx8w/ Participants can register for the teleconference here: https://s1.c-conf.com/diamondpass/10049152-x745re.html About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focu

MELBOURNE, Australia and INDIANAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 March 2025 (Q1 2025). All figures are in $US unless stated otherwise. Strong Q1 2025 revenue growth Q1 2025 unaudited revenue of approximately $186 million represents an increase of 62% over the prior year corresponding quarter (Q1 2024: $115M) and a quarter-over-quarter increase of 31% (Q4 2024: $142 million) and includes: $151 million from global sales of Illuccix®, up 35% over the prior year corresponding quarter (Q1 2024: $112 million

MELBOURNE, Australia and INDIANAPOLIS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces it has completed the acquisition of RLS (USA) Inc. (RLS; RLS Radiopharmacies), America's only Joint Commission-accredited radiopharmacy network distributing PET1, SPECT2 and therapeutic radiopharmaceuticals. The acquisition immediately enhances Telix's presence in the United States (U.S.), with a network of over 30 radiopharmacies3 dispensing radiopharmaceuticals manufactured by Telix and other companies, while bringing a team of highly-skilled and multi-disciplinary radiopharmaceutical professionals into the Company. Th